---
schema_version: "secwatch.filing_event.v1"
accession: "0001023024-26-000071"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2026-08-24T11:01:19+00:00"
generated_at: "2026-08-24T11:05:39.270670+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ANI Pharmaceuticals appoints Henry Gosebruch to board; director Shanmugam resigns

## Summary
- Henry Gosebruch appointed to ANI board effective Aug 19, 2026; term expires at 2027 annual meeting.
- Gosebruch is CEO of Lakefront Biotherapeutics (formerly Galapagos) since May 2025; ex-CEO of Neumora, ex-EVP Chief Strategy Officer at AbbVie.
- Gosebruch receives initial restricted stock award with grant date fair value $525,000, vesting in 3 equal annual installments.
- Samy Shanmugam resigned as director effective Aug 23, 2026; remains Head of R&D and COO of New Jersey Operations.
- Gosebruch brings 30+ years experience; expected to strengthen business development and capital allocation as ANI accelerates Rare Disease transformation.

## SEC filing metadata
- accession: 0001023024-26-000071
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2026-08-24T11:01:19+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000071/0001023024-26-000071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000071/ani-20260819.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001023024-26-000071
- JSON: https://secwatch.observer/filing/0001023024-26-000071.json
- Plain text: https://secwatch.observer/filing/0001023024-26-000071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.